US Skin Cancer Drug Pipeline Analysis
The market for skin cancer in the US is expected to grow significantly owing to reasons like increasing number of patients and entry of new therapies which are in the pipeline. Additionally, the organic growth of key marketed drugs is also another major factor driving the growth in the US market. Of the different types of skin cancers in the US, Melanoma is the most common. Though this segment accounts for just 5% of the overall US skin cancer market, it is a major factor causing 75% deaths in the region. Also, the US market witnesses a greater use of adjuvant therapy to treat early stage melanoma, as compared to the other regions.
With surgery being along with early detection is by far the most successful method of treating skin cancer in the US, the risk of recurrence in the patients is high. Additionally, the survival rates for the patients with advanced stages of the disease are very low. This has been a major challenge in the US market and companies investing in this space have been continuously researching on various options to improve the survival rates.
“US Skin Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of skin cancer in US. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US skin cancer drug market based upon development process.
Following parameters for each drug profile in development phase are covered in “US Skin Cancer Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Orphan Designation by Indication, Country & Organisation
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 3
- Preclinical: 29
- Clinical: 5
- Phase 0: 1
- Phase-I: 29
- Phase-I/II: 18
- Phase-II: 41
- Phase-III: 13
- Registered: 4
- Marketed: 18
- Unknown: 1
2. SKIN CANCER DRUG CLININCAL PHASE: UNKNOWN
2.1 Overview
2.2 Skin Cancer Drug Profile in Clinical Phase
3. SKIN CANCER DRUG CLININCAL PHASE: RESEARCH
3.1 Overview
3.2 Skin Cancer Drug Profile in Clinical Phase
4. SKIN CANCER DRUG CLININCAL PHASE: PRECLINICAL
4.1 Overview
4.2 Skin Cancer Drug Profile in Clinical Phase
5. SKIN CANCER DRUG CLININCAL PHASE: CLINICAL
5.1 Overview
5.2 Skin Cancer Drug Profile in Clinical Phase
6. SKIN CANCER DRUG CLININCAL PHASE: PHASE-0
6.1 Overview
6.2 Skin Cancer Drug Profile in Clinical Phase
7. SKIN CANCER DRUG CLININCAL PHASE: PHASE-I
7.1 Overview
7.2 Skin Cancer Drug Profile in Clinical Phase
8. SKIN CANCER DRUG CLININCAL PHASE: PHASE-I/II
8.1 Overview
8.2 Skin Cancer Drug Profile in Clinical Phase
9. SKIN CANCER DRUG CLININCAL PHASE: PHASE-II
9.1 Overview
9.2 Skin Cancer Drug Profile in Clinical Phase
10. SKIN CANCER DRUG CLININCAL PHASE: PHASE-III
10.1 Overview
10.2 Skin Cancer Drug Profile in Clinical Phase
11. SKIN CANCER DRUG CLININCAL PHASE: REGISTERED
11.1 Overview
11.2 Skin Cancer Drug Profile in Clinical Phase
12. MARKETED
12.1 Overview
12.2 Marketed Skin Cancer Drug Profile
EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:
- Alternate Names
- Originator & Owner
- Collaborator
- Technology Provider
- Licensee
- Highest Development Phase
- Indications
- Class
- Mechanism of Action
- ATC code
- Designated Brand Name & Orphan Designation
The market for skin cancer in the US is expected to grow significantly owing to reasons like increasing number of patients and entry of new therapies which are in the pipeline. Additionally, the organic growth of key marketed drugs is also another major factor driving the growth in the US market. Of the different types of skin cancers in the US, Melanoma is the most common. Though this segment accounts for just 5% of the overall US skin cancer market, it is a major factor causing xx% deaths in the region. Also, the US market witnesses a greater use of adjuvant therapy to treat early stage melanoma, as compared to the other regions.
With surgery being along with early detection is by far the most successful method of treating skin cancer in the US, the risk of recurrence in the patients is high. Additionally, the survival rates for the patients with advanced stages of the disease are very low. This has been a major challenge in the US market and companies investing in this space have been continuously researching on various options to improve the survival rates.
In 2010, the total incidence of skin cancer in the US was estimated to be close to xx million, which is expected to increase to xx million by 2017. Additionally, on the global front, a decrease of xx in the stratospheric ozone is also likely to lead to xx additional cases of non-melanoma skin cancers and xx melanoma cases annually. Though the early diagnosis and treatment of skin cancer increase the survival rates significantly, the major challenge is that the drugs currently available in the market are highly toxic in nature. This has led to low response rates among patients.
Additionally, there are no specific drugs approved by the FDA for melanoma for the past decade. Thus, currently the patients of skin cancer are treated with chemotherapy (dacarbazine) and IL-2 (Proleukin). Both of these treatments have not shown any significant improvement in the overall survival rates, which has led to a high degree of unmet need among the patients.
It is most likely that in the future, the new launches of drugs specially for melanoma treatment would lead to more affordable and accessible options for the patients. Some of the drugs in the pipeline have the potential to be blockbusters for targeted therapies. By 2017, close to 10 new drugs are likely to be launched, with a few major drugs losing out on their patents in this period. With the expected entry of biosimilars/generics which would be of lower costs, the growth in the market is likely to be restrained. However, an increase in the adoption rates and more accessibility at lower prices is likely to be observed with the entry of generics into the market.
In the future, the pharma and biotech companies would require to invest significantly in developing novel medications which would lead to improvement in survival rates for metastatic melanoma and less toxicity. These new cancer therapies would demand premium pricing which would inturn result in higher revenue for the drug makers.
However, since the patients do not have sufficient options for reimbursements, they would tend to opt for biosimilars instead of expensive novel therapies. In order to overcome this, the pharmaceuticals and biotech companies would be required to offer more personalized therapies with the objective of providing the appropriate drug at the right dose for each patient. Technologies like genomic and proteomic data profiling are expected to provide novel molecular markers which would enable the process of detecting skin cancer progression. This is expected to generate significant opportunities for developing more effective therapies for skin cancer.
